Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad Gets Phase IIb HIV Maturation Inhibitor From Panacos For $7M

This article was originally published in The Pink Sheet Daily

Executive Summary

Soon to split from parent Myriad Genetics, biotech obtains compound from Panacos without milestone or royalty obligations.

You may also be interested in...



Bristol Advancing Two New Mechanisms In HIV, With Focus On Treatment-Experienced Patients

An attachment inhibitor entering Phase III may offer a new option for patients who have outlived the utility of other antiretrovirals. Bristol also is advancing a second-generation maturation inhibitor of HIV into Phase IIb studies, hoping to succeed where other candidates failed to address viral mutation.

Myriad Agrees To Acquire Javelin In Stock-Swap Transaction

The Myriad Genetics spinout is hastening its progress into a commercial company by buying Javelin, although investors are grumbling about the deal terms.

Myriad Agrees To Acquire Javelin In Stock-Swap Transaction

The Myriad Genetics spinout is hastening its progress into a commercial company by buying Javelin, although investors are grumbling about the deal terms.

Related Content

Topics

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel